Anti-Trypanosoma cruzi agent-9 is a topoisomerase II inhibitor. Anti-Trypanosoma cruzi agent-9 inhibits the growth of Trypanosoma cruzi and Leishmania donovani.

anti-TNBC agent-13, a NO donor-Aurovertin B conjugate, is a ferroptosis inducer. anti-TNBC agent-13 inhibits GPX4 activity and leads to triple-negative breast cancer (TNBC) cell death. anti-TNBC agent-13 can be used for the research of triple-negative breast cancer.

Antiproliferative agent-76 (Compound II-2) is an 8-sulfonamidoquinoline derivative and a selective anticancer agent. Antiproliferative agent-76 blocks the NF-κB and WNT signaling pathways. Antiproliferative agent-76 promotes cancer cell Apoptosis. Antiproliferative agent-76 exhibits anticancer activity against colorectal cancer and leukemia.

Antiproliferative agent-74 (Compound 19a) is an anti-proliferative agent. Antiproliferative agent-74 suppresses Twist1 expression, induces weak Apoptosis. Antiproliferative agent-74 displays anti-proliferative activity against non-small cell lung cancer cells.

Antiparasitic agent-39 (Compound 14) is a selective antiparasitic agent and Deferasirox derivative. Antiparasitic agent-39 reduces the mitochondrial membrane potential. Antiparasitic agent-39 shows antiparasitic activity against T. brucei, T. gambiense, L. Mexicana, T. gondii, B. divergens, P. falciparum with EC50s of 4.2 nM, 10.4 nM, 52.0 nM, 17.0 nM, 41.2 nM, 54.8 nM, respectively.

Antiparasitic agent-37 (Compound 4717) is an orally active antiparasitic agent. Antiparasitic agent-37 exhibits activity against S. mansoni in mice. Antiparasitic agent-37 has an oral LD50 of 0.4 g/kg in mice after a single dose. Antiparasitic agent-37 can be used for the research of infectious diseases.

Antiparasitic agent-30 is a potent adenosine kinase TbrAK modulator and antitrypanosomal agent. Antiparasitic agent-30 exhibits significant inhibitory activity against Trypanosoma brucei rhodesiense, while enhancing the activity of recombinant TbrAK(EC50=38 nM, Ka=75 nM-497 nM). Antiparasitic agent-30 exerts its pharmacological effects by eliminating intrinsic substrate inhibition and hyperactivating TbrAK in Trypanosoma brucei rhodesiense. Antiparasitic agent-30 serves as a valuable tool molecule for studying acute African human trypanosomiasis (sleeping sickness).

Antioxidant 245 (AO-245) is a hindered phenol antioxidant. Antioxidant 245 can be used in the research of nanocomposites.

anti-NSCLC agent-2 (compound 6o) is a SLC7A11 and GPX4 inhibitor that reduces the expression of ferroptosis key regulators SLC7A11 and GPX4. anti-NSCLC agent-2 disrupts redox homeostasis, depletes glutathione, accumulates lipid peroxides, and induces ferroptosis in non-small cell lung cancer cells. anti-NSCLC agent-2 is applicable to research related to non-small cell lung cancer.

Anti-MRSA agent 37 (Compound 5B) is an antibacterial agent against methicillin-resistant Staphylococcus aureus (MRSA) (MIC=0.25-0.5 μg/mL). Anti-MRSA agent 37 inhibits biofilm formation, disrupts cell wall integrit, attacks cell membrane and induces oxidative stress. Anti-MRSA agent 37 is promising for research of MRSA-related diseases such as skin infections.

Anti-MRSA agent 36 (Compound III13) is an antibacterial agent with strong anti MRSA activity (MIC = 1 μg/mL). Anti-MRSA agent 36 targets phosphatidylglycerol (PG) on bacterial membranes, disrupting membrane integrity, leading to DNA leakage and increased ROS. Anti-MRSA agent 36 has advantages such as low cytotoxicity, low hemolysis, difficulty in inducing drug resistance, and good plasma stability. Anti-MRSA agent 36 can be used for the study of skin abscess and systemic infection models.

Antimicrobial agent-46 is a inhibitor of Salmonella typhimurium serine acetyltransferase (StSAT) with an IC50 of 48.6 μM. Antimicrobial agent-46 inhibits bacterial growth in minimal medium lacking cysteine (LB 20%). Antimicrobial agent-46 exerts its effect by targeting the cysteine biosynthesis pathway, which is crucial for bacterial persistence and adaptability. Antimicrobial agent-46 exhibits antibacterial activity against the Gram-negative bacterium Escherichia coli. Antimicrobial agent-46 can be used in infection-related research .

Antimetastatic agent-1 (Compound A-23) is a MET inhibitor. Antimetastatic agent-1 can inhibit cancer metastasis.

Antileishmanial agent-36 (compound 4f) is an indole-dihydropyrimidinone derivative with anti-leishmanial activity. Antileishmanial agent-36 induces reactive oxygen species (ROS)-mediated mitochondrial dysfunction and apoptosis. Antileishmanial agent-36 exhibits potent activity against L. donovani (IC50 =4.54 μM) with low cytotoxicity against J774.1 macrophage. Antileishmanial agent-36 clears the parasite burden in a visceral leishmaniasis (VL) model. Antileishmanial agent-36 can be used for VL research.

Anti-Influenza agent 10 (Compound 41) is an influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor. Anti-Influenza agent 10 exhibits potent antiviral activity against A/PR/8/34(H1N1) with an IC50 of 0.29μM and a KD of 4.11 μM. Anti-Influenza agent 10 can inhibit the assembly of the viral RdRp complex by disrupting the protein interaction between PA and PB1 subunits, thereby blocking the transcription and replication of the viral genome. Anti-Influenza agent 10 shows significant broad-spectrum effects on multiple influenza virus strains, such as H3N2, H3N8 and H9N2 with IC50 values of 3.96, 1.91 and 1.45 μM. Anti-Influenza agent 10 can be used for the research of influenza A Virus Infection.

Antifungal agent 151 is a Prp8 intein inhibitor that inhibits the self-splicing process of the Prp8 intein, preventing maturation of the Prp8 protein. Antifungal agent 151 exerts in vitro antifungal activity against Cryptococcus neoformans and Cryptococcus gattii. Antifungal agent 151 can be used for the research of cryptococcus pneumonia.

Antifungal agent 143 is potent antifungal agent which also exihibits antibacterial activity. Antifungal agent 143 inhibits growth of Candida albicans and Aspergillus niger, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pyogenes. Antifungal agent 143 can be used for antimicrobial research.

Anticancer agent 306 is a spiro tetramic acid derivative and a inhibitor of MMP1, MMP7 and PLK1. Anticancer agent 306 exerts antiproliferative activity against H1299, RKO and MCF-7 cells with IC50 values of 19.25 μM, 3.29 μM and 102.36 μM, respectively. Anticancer agent 306 can up-regulate p21 protein and down-regulate CCND1 and CCNB1 proteins to induce cell cycle arrest, regulate the expression of Bcl-2 and Bax to induce cell apoptosis. Anticancer agent 306 can down-regulate MMP1 and MMP7 proteins to inhibit tumor invasion and metastasis. Anticancer agent 306 can be used for the research of lung cancer, colorectal cancer, breast cancer.

Anticancer agent 302 (Example 1) is an anticancer agent. Anticancer agent 302 has a DC50 value of 199 nM for Cyclin E1 and an IC50 value of 133 nM for pRB. Anticancer agent 302 can be used for tumor research.

Anticancer agent 285 is an orally active anticancer agent with highly effective and selective haspin-inhibiting IC50 = 18 nM) activity. Anticancer agent 285 can be used for the study of colorectal cancer[1].

Antibacterial agent 339 is an antibacterial agent. Antibacterial agent 339 inhibits the growth of Fusarium oxysporum f.sp.cubense Race 4 with a MIC of 50.5 μM. Antibacterial agent 339 shows low toxicity in Kunming mice. FLT3-IN-30 can be used for the research of banana wilt.

Antibacterial agent 332 is an inhibitor of DsbA from Escherichia coli (EcDsbA). Antibacterial agent 332 reduces the swarming motility of Escherichia coli without affecting bacterial growth. Antibacterial agent 332 can be used in the research of bacterial infections caused by Escherichia coli.

Antibacterial agent 328 is a enoyl-ACP reductase (InhA) inhibitor and antimycobacterial agent. Antibacterial agent 328 blocks mycolic acid biosynthesis in Mycobacterium tuberculosis. Antibacterial agent 328 acts on both drug-resistant and drug-susceptible Mycobacterium tuberculosis strains. Antibacterial agent 328 exhibits favorable pharmacokinetic properties, drug-likeness, and a safety-related selectivity index. Antibacterial agent 328 can be used for research on tuberculosis.

Antifungal agent 147 (compound 2) is a lipophilic antibacterial agent with dark toxicity. Antifungal agent 147 shows a phototoxic effect on S. aureus and E. coli. Antifungal agent 147 can penetrate the bacterial cell membrane and disturb its structure, leading to dark toxicity. Antifungal agent 147 can be used for bacteria infection research.

Antibacterial agent 313 (Compound 20) is a broad-spectrum antibacterial agent. Antibacterial agent 313 can be used for research of bacterial infection.

Antibacterial agent 310 (compound 2) is a bis-benzimidazole-derived chelating ligand exhibiting antibacterial activity. Antibacterial agent 310 shows inhibition activity against intracellular viruses. Antibacterial agent can be used for antibacterial research.

Antibacterial agent 308 (Compound A25) is an antibacterial agent. Antibacterial agent 308 selectively targets bacterial membranes by binding phosphatidylethanolamine, thereby disrupting membrane polarization, elevating intracellular ROS levels. Antibacterial agent 308 shows significant anti-biofilm activity against S. aureus. Antibacterial agent 308 demonstrates potent anti-MRSA activity.

Anordrin is a contraceptive agent. Anordrin exhibits estrogenicites and can induce decrease in serum progesterone levels in rat models. Anordrin inhibits endometrial epithelial cell mitosis and NAFLD induced by Tamoxifen in mouse uterus and liver as an anti-estrogenic and estrogenic agent.

Androgen receptor degrader-6 is a blood-brain barrier-permeable AR degrader. Androgen receptor degrader-6 inhibits the chaperone activity of HSP27 and disrupts the HSP27-AR complex. Androgen receptor degrader-6 promotes the degradation of wild-type and mutant AR, reduces AR protein levels, and inhibits the growth of glioblastoma cells. Androgen receptor degrader-6 can be used in glioblastoma research.

Analgesic agent-4 is an adenosine A3AR ligand with analgesic/antinociceptive activity. Analgesic agent-4 inhibits writhing responses in mice and exhibits dose-dependent activity in the acetic acid-induced mouse writhing model. Analgesic agent-4 can be used in the research of pain-related diseases.